Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetravalent recombinant norovirus vaccine (Pichia pastoris)
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This tetravalent recombinant norovirus vaccine is a virus-like particle (VLP) vaccine developed by Beijing Zhifei Green Bamboo Biopharmaceutical, a subsidiary of Chongqing Zhifei Biological Products. The vaccine is produced using a *Pichia pastoris* (yeast) expression system and is designed to prevent acute gastroenteritis caused by norovirus. It targets four distinct genotypes of the virus—GI.1, GII.4, GII.3, and GII.17—which are responsible for the majority of norovirus outbreaks globally. By presenting non-infectious VLPs that structurally resemble the actual virus, the vaccine elicits a robust immune response, primarily through the induction of neutralizing antibodies against the viral capsid proteins.
- Other names
- Zhifei norovirus vaccinerecombinant norovirus VLP vaccinerecombinant norovirus tetravalent (GI.1/GII.4/GII.3/GII.17) VLP vaccine
02
Targets
GII.3 VP1 (Norovirus GII.3 VP1)GII.4 VP1 (Norovirus GII.4 VP1)
Beyond the preview
Go deeper on tetravalent recombinant norovirus vaccine (Pichia pastoris).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetravalent recombinant norovirus vaccine (Pichia pastoris).